Gothenburg, Sweden 9/15/11; Paris, France 9/15/11; Paris, France 11/2/11; Paris, France 11/4/11—Publicly held genome-engineering firm Cellectis has acquired Sweden’s Cellartis for 1.93 million shares and €16.4 million ($ 22.5 million = €0.73 = $1) in cash. Cellartis is a provider of stem cell–derived products and technologies, including human embryonic stem cell–derived hepatocytes and cardiomyocytes used for drug discovery. “The acquisition of Cellartis is in line with Cellectis’ strategy to become the global market leader for stem cell–based in vitro models and related technologies,” stated Cellectis Chairman and CEO André Choulika. “It will make it possible to considerably accelerate our development in this field, while enhancing our commercial offers, which are revolutionizing research and development for new applications across all life science industries.” Cellectis will combine its Ectycell business, which is focused on stem cells, with Cellartis to provide stem cell–derived in vitro R&D tools. In connection with the acquisition, Cellectis completed a €50 million ($68 million) financing round through the sale of bonds to the private-public French Strategic Investment Fund and French industrialist Pierre Bastid.